As previously disclosed, on October 1, 2026, Tonix Pharmaceuticals Holding Corp. (the “Company”) received a notice (the “Notice”) from Dr. Reddy’s Laboratories Ltd. and Dr. Reddy’s Laboratories, Inc. (collectively, “DRL”) stating that DRL filed an Abbreviated New Drug Application (“ANDA”) containing a Paragraph IV patent certification with the U.S. Food and Drug Administration (“FDA”) for a generic version of the Company’s drug, TONMYA® (cyclobenzaprine hydrochloride) sublingual tablets, 2.8 mg. The Notice states that the Paragraph IV patent certification was made with respect to U.S. Patent Nos. 9,636,408, 9,956,188, 10,117,936 and 10,864,175 listed in the FDA’s Approved Drug Products with Therapeutic Equivalence Evaluations, commonly known as the Orange Book. A Paragraph IV patent certification is a certification by a generic applicant that, in the opinion of that applicant, the patent listed in the Orange Book for a branded product is invalid, unenforceable, or will not be infringed by the manufacture, use or sale of the generic product.
|
Tonix Pharmaceuticals Holding Corp. is a biopharmaceutical company developing and commercializing therapies for central nervous system disorders, immunology, infectious diseases, and rare diseases. The company markets TONMYA, a sublingual cyclobenzaprine formulation for fibromyalgia, and two sumatriptan products for acute migraine: Zembrace SymTouch and Tosymra. Its development pipeline includes TNX-102 SL for major depressive disorder and acute stress disorder, TNX-4800 for Lyme disease prevention, TNX-1500 for transplant rejection and autoimmune diseases, TNX-1300 for cocaine intoxication, and TNX-2900 for Prader-Willi syndrome. Preclinical programs include TNX-801, a live virus vaccine for mpox and smallpox, TNX-4200, a broad-spectrum antiviral, TNX-1700 for gastric and colorectal cancer, and TNX-4900 for neuropathic pain. The company collaborates with academic institutions such as the University of North Carolina and receives funding from the U.S. Department of Defense for specific research programs. Summarised from the company's own disclosures, fiscal year ended Mar 2026 |
Industry Biotechnology | Homepage tonixpharma.com |
| Sector Healthcare | IR page ir.tonixpharma.com | |
|
Tags
central nervous system disorders, fibromyalgia, migraine, infectious diseases, rare diseases, vaccines, monoclonal antibodies, neuropathic pain, autoimmune diseases, biodefense, TONMYA, Zembrace SymTouch, Tosymra, TNX-102 SL, TNX-4800, TNX-1500, TNX-1300, TNX-2900, TNX-801, TNX-4200, TNX-1700, TNX-4900
|
Press page ir.tonixpharma.com/news-events/press-releases |
Metrics
| Valuation | |
|---|---|
| Market cap | $ 77.654M |
| Market cap (USD) | $ 77.654M |
| P/E | -0.32 |
| PEG | — |
| P/BV | 0.39 |
| P/S | 1.80 |
| P/OCF | -0.47 |
| P/FCF | -0.46 |
| Dividend yield | — |
| Turnover / mcap | — |
| Returns | |
|---|---|
| ROE | -64.5% |
| ROI | -320.5% |
| ROIC | -243.6% |
| Profit margin | -946.2% |
| Growth | |
|---|---|
| Revenue growing | Yes |
| Profits growing | No |
| Revenue up 3y | — |
| Revenue up 5y | — |
| Earnings growth 3y (net profit CAGR) | — |
| Quality | |
|---|---|
| Profitable | No |
| Margin expanding | Yes |
| Buying back stock | — |
| Diluting (TTM) | Yes |
| Debt/Equity | — |
| Podcast bulls (TTM) | Sign up |
| Podcast bears (TTM) | Sign up |
| Podcast sentiment (TTM) | Sign up |
| Podcast sentiment % (TTM) | Sign up |
| News sentiment (TTM) | 65 |
| Quality score | -42.9% |
| Insiders | |
|---|---|
| Buys, 1w | Sign up |
| Buys, 1m | Sign up |
| Buys, 1y | Sign up |
| Sells, 1w | Sign up |
| Sells, 1m | Sign up |
| Sells, 1y | Sign up |
Sign up to see this company's insider trades
| Figure | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 | FY 2013 | FY 2012 | FY 2011 | FY 2010 | FY 2009 | FY 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 13.107M | 10.094M | 7.768M | — | — | — | — | 0 | — | — | — | — | — | — | — | — | — | — |
| Net profit | -124.021M | -130.036M | -116.658M | -110.218M | -92.287M | -50.463M | -28.618M | -32.097M | -21.123M | -38.842M | -48.054M | -27.616M | -10.884M | -9.45M | -3.47M | -1.964M | — | — |
| Free cash flow | -103.213M | -61.045M | -109.898M | -146.2M | -110.864M | -57.13M | -26.7M | — | -19.133M | -37.381M | -42.646M | -23.159M | -8.532M | -5.749M | -2.64M | -1.268M | — | — |
| Figure | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 | FY 2013 | FY 2012 | FY 2011 | FY 2010 | FY 2009 | FY 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Share price | 15.62 | 0.33 | 0.4 | 1.71 | 0.61 | 0.68 | 1.16 | 3.44 | 3.61 | 0.41 | 5.18 | — | 3.65 | — | — | — | — | — |
| Price performance 12m | 46.38 | -0.18 | -0.76 | 1.8 | -0.1 | -0.41 | -0.75 | — | 7.8 | -0.92 | — | — | — | — | — | — | — | — |
Filed figures
Lines the statements and their notes report beside the headline figures, read from the filings' XBRL as filed (no restatement applied), with figures computed from one filing's own lines. Cash-flow lines carry their cash direction: an outflow is negative. Each period links to its filing; a figure's period, report date and tag are in its tooltip.
| Figure | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Balance sheet detail | ||||||||||
| Trade receivables (USD) | — | — | — | — | — | — | — | — | 3.68M | 6.27M |
| ↳ YoY growth | +70.3% | |||||||||
| Borrowings, current (USD) | — | — | — | — | — | — | — | 2.35M | 2.82M | — |
| Borrowings, non-current (USD) | — | — | — | — | — | — | — | 6.56M | 4.67M | — |
| Lease liabilities (USD) | — | — | — | 358,000 | 1.31M | 956,000 | 760,000 | 902,000 | 632,000 | 1.31M |
| Cash and deposits (USD) | 18.9M | 25.5M | 25M | 11.2M | 77.1M | 179M | 120M | 24.9M | 98.8M | 208M |
| Intangible assets (USD) | 120,000 | 120,000 | 120,000 | 120,000 | 120,000 | 120,000 | 120,000 | 9.74M | 120,000 | 120,000 |
| Right-of-use assets (USD) | — | — | — | 356,000 | 1.26M | 914,000 | 715,000 | 824,000 | 565,000 | 1.54M |
| Net debt (borrowings + leases - cash) (USD) | — | — | — | — | — | — | — | -15.1M | -90.7M | — |
| Cash flow detail | ||||||||||
| Operating cash flow (USD) | -37.3M | -19.1M | -24M | -26.7M | -48.6M | -75.6M | -98.1M | -102M | -60.9M | -99.8M |
| Purchases of property, plant and equipment (USD) | -66,000 | -5,000 | -6,000 | -17,000 | -8.56M | -35.3M | -48.1M | -7.9M | -120,000 | -3.37M |
| Change in receivables (cash effect) (USD) | — | — | — | — | — | — | — | — | -3.68M | -2.62M |
| Change in inventories (cash effect) (USD) | — | — | — | — | — | — | — | 61,000 | 3.74M | 1.73M |
| Change in payables (cash effect) (USD) | — | 424,000 | 106,000 | — | — | — | — | — | — | — |
| Share buybacks (cash effect) (USD) | — | — | — | — | — | — | — | -14M | — | -13.8M |
| Interest paid (cash effect) (USD) | — | — | — | — | — | — | — | -88,000 | -1.23M | -89,000 |
| Income taxes paid (cash effect) (USD) | — | -65,000 | -82,000 | — | — | — | — | — | — | — |
| Share-based compensation (USD) | 3.27M | 1.79M | 1.63M | 1.46M | 2.88M | 7.9M | 10.9M | 9.28M | 4.78M | 6.02M |
| Operating cash flow before change in receivables (USD) | — | — | — | — | — | — | — | — | -57.2M | -97.2M |
| Free cash flow (OCF - PPE - intangibles) (USD) | -37.4M | -19.1M | -24M | -26.7M | -57.1M | -111M | -146M | -110M | -61M | -103M |
| Income detail | ||||||||||
| Research and development expense (USD) | 28.5M | 13.3M | 17.6M | 18.2M | 36.2M | 68.8M | 81.9M | 86.7M | 40M | 44.5M |
| ↳ 5y CAGR | +89.8% | +38.9% | +30.4% | -0.5% | +0.4% | +19.3% | +43.7% | +37.6% | +17.1% | +4.2% |
| Total comprehensive income (USD) | -38.8M | -21.1M | -26.1M | -28.6M | -50.5M | -92.3M | -110M | -117M | -130M | -124M |
| Comprehensive income to owners (USD) | -38.8M | -21.1M | -26.1M | -28.6M | -50.5M | -92.3M | -110M | -117M | -130M | -124M |
| Reported | Apr 13, 2017 | Mar 18, 2019 | Mar 24, 2020 | Mar 24, 2020 | Mar 15, 2021 | Mar 14, 2022 | Aug 10, 2023 | Mar 18, 2025 | Mar 18, 2025 | Mar 12, 2026 |
Sign up to see institutional holdings
Sign UpPodcast Mentions
Sign up to see podcast mentions and sentiment
Sign UpMaterial events reported to the SEC on Form 8-K or 6-K, newest first. The link opens the filing itself on EDGAR. Press releases from the company's own website, newest first.
Approximately $163 million in cash and cash equivalents as of September 30, 2026
Strategic focus on supporting TONMYA growth and advancing core clinical programs
Conference call today at 8:30 a.m. ET
Berkeley Heights, N.J., Nov. 9, 2026 (GlobeNewswire) — Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a fully integrated, commercial-stage biopharmaceutical company, today announced financial results for the quarter ended September 30, 2026, and provided an overview of recent operational highlights.
“We delivered another strong quarter for TONMYA, with net sales up 37% over the second quarter,” said Seth Lederman, M.D., President and Chief Executive Officer of Tonix Pharmaceuticals. “Total prescriptions, new prescriptions, and refills also increased. Payer access expanded to include two commercial group purchasing organization (GPO) agreements, two managed Medicare agreements, and Medicaid access in almost every state. This expanded access contributed to third quarter sales growth.
November 04, 2026 7:00am EST Download as PDF
BERKELEY HEIGHTS, N.J., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or “the Company”), a fully integrated, commercial-stage biopharmaceutical company, today announced that management will present and host 1x1 meetings at Guggenheim’s 3rd Annual Healthcare Innovation Conference in Boston, Massachusetts on Tuesday, November 10, 2026.
Guggenheim’s 3rd Annual Healthcare Innovation Conference
Company Presentation
Presenter: Seth Lederman, M.D., President and Chief Executive Officer of Tonix Pharmaceuticals
Date: Tuesday November 10, 2026
Presentation Time: 4:00-4:25 p.m. ET
A live webcast and replay will be available under the News & Events tab in the Investors section of the Tonix website at https://ir.tonixpharma.com/ .
Tonix Pharmaceuticals Holding Corp.
Tonix Pharmaceuticals* is a fully integrated, commercial-stage biopharmaceutical company focused on central nervous system (CNS) disorders, infectious diseases, and immunology conditions with high unmet medical needs. TONMYA® (cyclobenzaprine HCl sublingual tablets 2.8 mg), the Company’s flagship internally conceived and developed medicine, is the first medicine approved for fibromyalgia in more than 15 years. Tonix’s CNS commercial infrastructure supports its marketed products, including its acute migraine products, Zembrace® SymTouch® (sumatriptan injection 3 mg) and Tosymra® (sumatriptan nasal spray 10 mg). Tonix is extending the science behind TONMYA in Phase 2 clinical studies to evaluate the potential of TNX-102 SL in major depressive disorder and acute stress disorder/acute stress reaction. Tonix is also advancing a pipeline of infectious disease programs, including Phase 2-ready monoclonal antibody TNX-4800 (anti-OspA mAb) for Lyme disease prevention in the U.S., and TNX-801 (horsepox, live virus vaccine), a vaccine in development for the prevention of mpox and smallpox. Within immunology, TNX-1500 (anti-CD40L mAb) is a Phase 2-ready, third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection. To learn more, visit www.tonixpharma.com
.
*Tonix’s product development candidates, including TNX-102 SL for new, unapproved indications, are investigational new drugs or biologics. Their efficacy and safety have not been established for the indications under investigation, and they have not been approved for these uses.
Zembrace SymTouch and Tosymra are registered trademarks of Tonix Medicines. TONMYA is a registered trademark of Tonix Pharma Limited. All other marks are the property of their respective owners.
Forward Looking Statements
Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as “anticipate,” “believe,” “forecast,” “estimate,” “expect,” and “intend,” among others. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, risks related to the failure to successfully launch and commercialize TONMYA® and any of our approved products; uncertainties of patent protection and litigation; risks related to the failure to obtain FDA clearances or approvals and noncompliance with FDA regulations; risks related to the timing and progress of clinical development of our product candidates; our need for additional financing; uncertainties of government or third-party payer reimbursement; limited research and development efforts and dependence upon third parties; and substantial competition. As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. Investors should read the risk factors set forth in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, as filed with the SEC on March 12, 2026, and periodic reports filed with the SEC on or after the date thereof. Except as required by law, Tonix does not undertake an obligation to update or revise any forward-looking statement. All of Tonix’s forward-looking statements are expressly qualified by all such risk factors and other cautionary statements. The information set forth herein speaks only as of the date of this press release.
Investor Contacts
Deborah Elson
Tonix Pharmaceuticals
[email protected]
Brian Korb
astr partners
(917) 653-5122
[email protected]
Media Contacts
Andrea Cohen
Sam Brown Inc.
(917) 209-7163
[email protected]
Source: Tonix Pharmaceuticals Holding Corp.
Released November 4, 2026
© 2026 Tonix Pharmaceuticals Holding Corp.
Prompts
Click prompts to add them under the company line, click again to take one out, then copy the result into your AI chat. Shared by Asian Century Stocks and Uncovered Thai Stocks. Thank you.
Company History
Name and ticker changes, and re-registrations under a new regulatory id. When a ticker stopped being used is not recorded, so former tickers are undated.
| Date | Change | Detail |
|---|---|---|
| Oct 20, 2011 | Renamed | TAMANDARE EXPLORATIONS INC. → TONIX PHARMACEUTICALS HOLDING CORP. |
ETFs Holding Tonix Pharmaceuticals Holding Corp.
Exchange-traded funds whose newest published daily portfolio holds one of the company's listings, largest weight first.
